Targeted therapy for short QT syndrome

Expert Opinion on Therapeutic Targets

Volumn 10, Issue 3, 2006, Pages 393-400

  Bjerregaard, Preben ^a   Jahangir, Arshad ^b   Gussak, Ihor ^c  

^a SAINT LOUIS UNIVERSITY HOSPITAL   (United States)

^b MAYO CLINIC   (United States)

^c eResearchTechnology Inc   (United States)

Author keywords

Channelopathy; Potassium channel mutation; Short QT syndrome (SQTS); Sudden cardiac death (SCD)

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIHYDROQUINIDINE; FLECAINIDE; IBUTILIDE; ION CHANNEL; MEXILETINE; NICORANDIL; POTASSIUM CHANNEL; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KCNQ1; REGULATOR PROTEIN; SOTALOL;

CLINICAL FEATURE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ELECTROCARDIOGRAPHY; EXTRASYSTOLE; GENE MUTATION; GENE THERAPY; GENE TRANSFER; GENETIC CODE; HEART ATRIUM FIBRILLATION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART VENTRICLE FIBRILLATION; HUMAN; PATHOPHYSIOLOGY; QRS COMPLEX; QT INTERVAL; QT PROLONGATION; REVIEW; SHORT QT SYNDROME;

ARRHYTHMIA; CARDIOVASCULAR AGENTS; DRUG DELIVERY SYSTEMS; GENE THERAPY; HUMANS; LONG QT SYNDROME; POTASSIUM CHANNELS, VOLTAGE-GATED;

EID: 33745464869     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.10.3.393     Document Type: Review

References (45)

1. JERVELL AL-NF: Congenital deaf-mutism, functional heart disease with prolongation of the QT interval and sudden cardiac death. Am. Heart J. (1957) 54:59-68.
2. GUSSAK I, BRUGADA P, BRUGADA J et al.: Idiopathic short QT interval: a new clinical syndrome? Cardiology (2000) 94:99-102.
3. GIUSTETTO C, WOLPERT C, ANTTONEN OM et al.: Clinical presentation of the patients with short QT syndrome. Heart Rhythm (2005) 2:S61.
4. BJERREGAARD P, GUSSAK I: Short QT syndrome: mechanisms, diagnosis and treatment. Nat. Clin. Pract. Cardiovasc. Med (2005) 2:84-87.
5. PRIORI SG, PANDIT SV, RIVOLTA I et al.: A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ. Res. (2005) 96:800-807.
6. GAITA F, GIUSTETTO C, BIANCHI F et al: Short QT syndrome. A familial cause of sudden death. Circulation (2003) 108:965-970
7. BRUGADA R, HONG K, DUMAINE R et al.: Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation (2004) 109:30-35.
8. BELLOCQ C, VAN GINNEKAN A, BEZZINA et al.: Mutation in the KCNQl gene leading to the short-QT-interval syndrome. Circulation (2004) 110:III-230.
9. HONG K, BJERREGAARD P, GUSSAK I, BRUGADA R: Short QT syndrome and atrial fibrillation caused by mutation in KCNH2 J. Cardiovasc. Electrophysiol. (2005) 16:394-396.
10. TESTER DJ, WILL ML, HAGLUND CM, ACKERMAN MJ: Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm (2005) 2:507-517.
11. WOLPERT C, SCHIMPF R, VELTMAN C, GIUSTETTO C, GAITA F, BORGGREFE M: Clinical characteristics and treatment of short QT syndrome. Expert Rev. Cardiovasc. Ther. (2005) 3(4):611-617.
12. EXTRAMIANA F, ANTZELEVITCH C: Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular-wedge model of short-QT syndrome. Circulation (2004) 110:3661-3666.
13. SCHIMPF R, BAUERSFELD U, GAITA F, WOLPERT C: Short QT syndrome: Successful prevention of sudden cardiac death in an adolescent by implantable cardioverter-defibrillator treatment for primary prophylaxis. Heart Rhythm (2005) 2:416-417.
14. GAITA F, GIUSTETTO C, BIANCHI F et al.: Short QT syndrome: pharmacological treatment. JACC (2004) 43:1494-1499,
15. BJERREGAARD P, GUSSAK I: Short QT syndrome. A.N.E. (2005) 10(4):1-5.
16. KHOSITSETH A, ACKERMAN MJ: Clinical evaluation, risk stratification, and management of congenital long QT syndrome. In: Cardiac Repolarization - Bridging Basic and Clinical Science, Gussak I, Antzelevitch C, Hammill SC, Shen W-K, Bjerregaard P (Eds.), Totowa Humana Press (2003):447-479.
17. JAHANGIR A, TERZIC A, SHEN WK: Antiarrhythmic drugs and future direction In: Cardiac Repolarization: Bridging Basic and Clinical Science, Gussak I Antzelevitch C, Hammill SC, Shen WK, Bjerregaard P (Eds.), Totowa: Humana Press. (2003):387-404.
18. MEMBERS OF THE SICILIAN GAMBIT: New approaches to antiarrhythmic therapy - Emerging therapeutic applications of the cell biology of cardiac arrhythmias. Eur. Heart J. (2001) 22:2148-2163.
19. YELLEN G: The voltage-gated potassium channels and their relatives. Nature (2002) 419:35-42.
20. Kr, inactivation by mutation N588K in KCNH2: a link to arrhythmogenesis in short QT syndrome. Cardiovasc. Res. (2005) 67(3):498-509.
21. + channel mutation in the "short QT syndrome": mechanism of gain-in-function determined at 37°C. Biochem. Biophys. Res. Commun. (2005) 334(2):441-449.
22. MILNES JT, CROCIANI O, ARCANGELI A, HANCOX JC, WITCHEL HJ: Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutation at F656 or Y652. Br. J. Pharmacol. (2003) 139:887-898.
23. PAUL AA, WITCHEL HJ, HANCOX JC: Inhibition of HERG potassium channel current by the Class Ia antiarrhythmic agent disopyramide. Biochem. Biophys. Res. Commun. (2001) 280:1243-1250.
24. WOLPERT C, SCHIMPF R, GIUSTETTO C et al: Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J. Cardiovasc. Electrophysiol. (2005) 16:54-58.
25. GOUAUX E, MACKINNON R: Principles of selective ion transport in channels and pumps. Science (2005) 310:1461-1465.
26. SANGUINETTI MC, CHEN J, FERNANDEZ D, KAMIYA K, MITCHESON J, SANCHEZ-CHAPULA JA: Physicochemical basis for binding and voltage-dependent block of hERG channels by structurally diversedrugs. Novartis Found. Symp. (2005) 266:159-166.
27. KAMIYA K, NIWA R, MITCHESON JS, SANGUINETTI MC: Molecular determinants of hERG channel block. Mol. Pharmacol. (2006) Epub ahead of print.
28. TRISTANI-FIROUZI M, SANGUINETTI MC: Structural determinants and biophysical properties of HERG and KCNQ1 channel gating. J. Mol. Cell. Cardiol. (2003) 35:27-35.
29. Ks, heterogeneity on action potential duration and its rate dependence: a simulation study. Circulation (1999) 99:2466-2474.
30. SHAH RR, HONDEGHEM LM: Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm (2005) 2:758-772.
31. Ks, participation in cardiac repolarization and repolarization reserve. Circulation (2005) 112:1384-1391.
32. KS channel function induced by an LQT5 mutation and other IsK mutants. EMBO J. (1999) 18:4137-4148.
33. Kr, potassium channels with HERG and is associated with cardiac arrhythmia. Cell (1999) 97:175-187.
34. MALYKHINA AP, SHOEB F, AKBARALI HI: Fenamate-induce enhancement of heterolgously expressed HERG currents in Xenopus oocytes. Eur. J. Pharmacol. (2002) 452:269-277.
35. ANDERSEN ME: Calmodulin kinase signaling in heart: an intriguing candidate target for therapy of myocardial dysfunction and arrhythmias. Pharmacol. Ther. (2005) 106:39-55.
36. + channels by calmodulin. Circ. Res. (2002) 90:E49-E57.
37. + current in cultured adult human atrial myocytes. Circ. Res. (1997) 80:572-579.
38. Kur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide. J. Pharmacol. Exp. Ther. (2005) 315:1362-1367.
39. ATP channel therapeutics at the bedside. J. Mol. Cell. Cardiol. (2005) 39:99-112.
40. + channel. J. Physiol. (2001) 531:645-660.
41. NEYROUD N, NUSS HB, LEPPO MK, MARBAN E, DONAHUE JK: Gene delivery to cardiac muscle. Methods Enzymol. (2002) 346:323-334.
42. MURATA M, CINGOLANI E, MCDONALD AD, DONAHUE JK, MARBAN E: Creation of a genetic calcium channel blocker by targeted gem gene transfer in the heart. Circ. Res. (2004) 95:398-405.
43. MIAKE J, MARBAN E, NUSS HB: Functional role of inward rectifier current in heart probed by Kir2.1 overexpression and dominant-negative suppression. J. Clin. Invest. (2003) 111:1529-1536.
44. + channels. Physiol. Rev. (2005) 85:33-47.
45. RODEN DM: Proarrhythmia as a pharmacogenomic entity: a critical review and formulation of a unifying hypothesis. Cardiovasc. Res. (2005) 67:419-425.